Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS
Shannon Raber, MS, CPNP, RN
Bridget Archambault, MSN, CPNP
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Integrating Molecular Testing into NSCLC Care
Geoffrey Oxnard, MD
Smarter Screening for Non-Small Cell Lung Cancer
Jobelle Baldonado, MD
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Laura Alder, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
The Importance of Multidisciplinary Coordination in NSCLC Care
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026 Scottsdale, Arizona
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
A New Era of Hope in Non-Small Cell Lung Cancer Care
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Christine Bestvina, MD
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 29, 2026
12:00 PM - 01:00 PM EDT
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Moving Toward Biomarker-Driven Care in Bladder Cancer
Benjamin Garmezy, MD
Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.